STAYBLE THERAPEUTIC’S PRESENTS POSITIVE INTERIM DATA
Stayble Therapeutics AB is currently conducting a phase 2b study with the drug candidate STA363. The company has analyzed blinded data and the results show continued good safety and tolerability and indicate good opportunities for a conclusive outcome of the study.Read more in the Press Release
Latest press releases
Stayble Therapeutics presented at Swedish Shareholders´ Association´s event Stora Aktiedagen Stockholm 2021
Stayble Therapeutics' CEO Andreas Gerward gave a presentation on 30 November 2021 at Stora Aktiedagen Stockholm 2021, an event arranged by Swedish Shareholders´ Association´s. The event, which takes...
SE - Stayble Therapeutics AB offentliggör kvartalsrapport för Q3 2021
Göteborg, 18 november 2021 – Stayble Therapeutics AB publicerar kvartalsrapport för tredje kvartalet (juli-september) 2021...
Bridging the therapeutic gap
About 30% of all patients with discogenic cLBP are helped by therapy such as analgesics and physiotherapy, and only 1% undergo spine surgery. Stayble’s product STA363 will bridge the gap between conservative and radical therapy to the benefit of millions of patients presently left on their own to cope with sustained and disabling pain.Our market
Treating the root cause of the disease. Not just the symptoms.
Instead of costly or time-consuming procedures, such as spinal fusion or long-term physiotherapy, our cLBP treatment is an easily performed, single injection procedure that stabilises the disc by transforming it to connective tissue. Unlike any other currently available treatment, this has the potential to permanently attenuate the pain significantly faster than surgical intervention.
An intervertebral disc consists of two main parts: the disc centre and the wall. The disc centre consists largely of a highly hydrated gel together with nucleus pulposus cells and fibroblasts.
DEGENERATED UNTREATED DISC
When a disc degenerates it becomes less stable and proinflammatory substances formed during the degenerative process can leak from the inner core of the disc. Pain-sensing nerves within and outside the wall of the disc are activated. These processes cause back pain.
By injecting STA363 directly into the degenerated intervertebral disc, the cells are triggered to produce collagen and the damaged disc is transformed into connective tissue. This helps restabilise the intervertebral segment and reduces leakage of proinflammatory substances.
Get in touch
We are always looking for passionate people who are interested in joining us to help realizing our vision. Please leave your contact details and we will get back to you firstname.lastname@example.org